Functional effects of sequence variations in the E6 and E2 genes of human papillomavirus 16 European and Asian variants

Journal of Medical Virology

Volumn 86, Issue 4, 2014, Pages 618-626

  Hang, Dong ^a   Gao, Lei ^a   Sun, Min ^a   Liu, Ying ^a   Ke, Yang ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

E2; E6; HPV16; LCR; Variants

Indexed keywords

E2; E6; HPV16; LCR; VARIANTS;

ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; CELL LINE, TUMOR; DNA, VIRAL; DNA-BINDING PROTEINS; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; HELA CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 84893788184     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23792     Document Type: Article

References (56)

1. Asadurian Y, Kurilin H, Lichtig H, Jackman A, Gonen P, Tommasino M, Zehbe I, Sherman L. 2007. Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol 79:1751-1760.
2. Bernard HU, Calleja-Macias IE, Dunn ST. 2006. Genome variation of human papillomavirus types: Phylogenetic and medical implications. Int J Cancer 118:1071-1076.
3. Bouvard V, Storey A, Pim D, Banks L. 1994. Characterization of the human papillomavirus E2 protein: Evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J 13:5451-5459.
4. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S. 2004. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by notch signaling and oncogenic Ras. J Virol 78:5934-5945.
5. Chan PK, Lam CW, Cheung TH, Li WW, Lo KW, Chan MY, Cheung JL, Xu LY, Cheng AF. 2002. Human papillomavirus type 16 intratypic variant infection and risk for cervical neoplasia in southern China. J Infect Dis 186:696-700.
6. Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, Tommasino M, Clifford GM. 2012. Human papillomavirus type 16 genetic variants: Phylogeny and classification based on E6 and LCR. J Virol 86:6855-6861.
7. Cornet I, Gheit T, Iannacone MR, Vignat J, Sylla BS, Del Mistro A, Franceschi S, Tommasino M, Clifford GM. 2013. HPV16 genetic variation and the development of cervical cancer worldwide. Br J Cancer 108:240-244.
8. Crook T, Tidy JA, Vousden KH. 1991. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547-556.
9. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. 2004. Classification of papillomaviruses. Virology 324:17-27.
10. Doorbar J. 2005. The papillomavirus life cycle. J Clin Virol 32:S7-S15.
11. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, Tan T, Halsey N, Jenkins D. 2009. Clinician's guide to human papillomavirus immunology: Knowns and unknowns. Lancet Infect Dis 9:347-356.
12. Eriksson A, Herron JR, Yamada T, Wheeler CM. 1999. Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region. J Gen Virol 80:595-600.
13. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, Tungteakkhun SS, Williams K, Duerksen-Hughes PJ. 2007. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 81:4116-4129.
14. Foster SA, Demers GW, Etscheid BG, Galloway DA. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68:5698-5705.
15. Gauthier JM, Dillner J, Yaniv M. 1991. Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res 19:7073-7079.
16. Gheit T, Cornet I, Clifford GM, Iftner T, Munk C, Tommasino M, Kjaer SK. 2011. Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol Biomarkers Prev 20:1315-1321.
17. Giri I, Yaniv M. 1988. Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J 7:2823-2829.
18. Grodzki M, Besson G, Clavel C, Arslan A, Franceschi S, Birembaut P, Tommasino M, Zehbe I. 2006. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev 15:820-822.
19. Hecht JL, Kadish AS, Jiang G, Burk RD. 1995. Genetic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. Int J Cancer 60:369-376.
20. Hu X, Pang T, Guo Z, Mazurenko N, Kisseljov F, Ponten J, Nister M. 2001. HPV16 E6 gene variations in invasive cervical squamous cell carcinoma and cancer in situ from Russian patients. Br J Cancer 84:791-795.
21. Huertas-Salgado A, Martin-Gamez DC, Moreno P, Murillo R, Bravo MM, Villa L, Molano M. 2011. E6 molecular variants of human papillomavirus (HPV) type 16: An updated and unified criterion for clustering and nomenclature. Virology 410:201-215.
22. Jang M, Rhee JE, Jang DH, Kim SS. 2011. Gene expression profiles are altered in human papillomavirus-16 E6 D25E-expressing cell lines. Virol J 8:453.
23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
24. Jeon S, Lambert PF. 1995. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92:1654-1658.
25. Kang S, Jeon YT, Kim JW, Park NH, Song YS, Kang SB, Lee HP. 2005. Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. Int J Gynecol Cancer 15:107-112.
26. Lichtig H, Algrisi M, Botzer LE, Abadi T, Verbitzky Y, Jackman A, Tommasino M, Zehbe I, Sherman L. 2006. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350:216-227.
27. Matsumoto K, Yoshikawa H, Nakagawa S, Tang X, Yasugi T, Kawana K, Sekiya S, Hirai Y, Kukimoto I, Kanda T, Taketani Y. 2000. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. Cancer Lett 156:159-165.
28. Matsumoto K, Yasugi T, Nakagawa S, Okubo M, Hirata R, Maeda H, Yoshikawa H, Taketani Y. 2003. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer 106:919-922.
29. Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, Coutlee F, Archambault J. 2012. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 86:94-107.
30. Niccoli S, Abraham S, Richard C, Zehbe I. 2012. The Asian-American E6 variant protein of human papillomavirus 16 alone is sufficient to promote immortalization, transformation and migration of primary human foreskin keratinocytes. J Virol 86:12384-12396.
31. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckere F, Sibler AP, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Trave G. 2006. Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21:665-678.
32. Ordonez RM, Espinosa AM, Sanchez-Gonzalez DJ, Armendariz-Borunda J, Berumen J. 2004. Enhanced oncogenicity of Asian-American human papillomavirus 16 is associated with impaired E2 repression of E6/E7 oncogene transcription. J Gen Virol 85:1433-1444.
33. Pillai MR, Hariharan R, Babu JM, Lakshmi S, Chiplunkar SV, Patkar M, Tongaonkar H, Dinshaw K, Jayshree RS, Reddy BK, Siddiqui M, Roychoudury S, Saha B, Abraham P, Gnanamony M, Peedicayil A, Subhashini J, Ram TS, Dey B, Sharma C, Jain SK, Singh N. 2009. Molecular variants of HPV-16 associated with cervical cancer in Indian population. Int J Cancer 125:91-103.
34. Richard C, Lanner C, Naryzhny SN, Sherman L, Lee H, Lambert PF, Zehbe I. 2010. The immortalizing and transforming ability of two common human papillomavirus 16 E6 variants with different prevalences in cervical cancer. Oncogene 29:3435-3445.
35. Romanczuk H, Thierry F, Howley PM. 1990. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol 64:2849-2859.
36. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Solomon D, Castle PE, Burk RD. 2010. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70:3159-3169.
37. Schweiger MR, Ottinger M, You J, Howley PM. 2007. Brd4-independent transcriptional repression function of the papillomavirus e2 proteins. J Virol 81:9612-9622.
38. Sichero L, Sobrinho JS, Villa LL. 2012. Oncogenic potential diverge among human papillomavirus type 16 natural variants. Virology 432:127-132.
39. Stoppler MC, Ching K, Stoppler H, Clancy K, Schlegel R, Icenogle J. 1996. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 70:6987-6993.
40. Sun M, Gao L, Liu Y, Zhao Y, Wang X, Pan Y, Ning T, Cai H, Yang H, Zhai W, Ke Y. 2012. Whole genome sequencing and evolutionary analysis of human papillomavirus type 16 in central China. Plos ONE 7:e36577.
41. Swan DC, Rajeevan M, Tortolero-Luna G, Follen M, Tucker RA, Unger ER. 2005. Human papillomavirus type 16 E2 and E6/E7 variants. Gynecol Oncol 96:695-700.
42. Thierry F, Yaniv M. 1987. The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region. EMBO J 6:3391-3397.
43. Thomas M, Pim D, Banks L. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700.
44. Wang SS, Hildesheim A. 2003. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 2003:35-40.
45. Wu Y, Chen Y, Li L, Yu G, He Y, Zhang Y. 2006. Analysis of mutations in the E6/E7 oncogenes and L1 gene of human papillomavirus 16 cervical cancer isolates from China. J Gen Virol 87:1181-1188.
46. Wu Y, Liu B, Lin W, Xu Y, Li L, Zhang Y, Chen S, Xu A. 2007. HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer. J Med Virol 79:439-446.
47. Xi LF, Kiviat NB, Hildesheim A, Galloway DA, Wheeler CM, Ho J, Koutsky LA. 2006. Human papillomavirus type 16 and 18 variants: Race-related distribution and persistence. J Natl Cancer Inst 98:1045-1052.
48. Xi LF, Kiviat NB, Wheeler CM, Kreimer A, Ho J, Koutsky LA. 2007. Risk of cervical intraepithelial neoplasia grade 2 or 3 after loop electrosurgical excision procedure associated with human papillomavirus type 16 variants. J Infect Dis 195:1340-1344.
49. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. 1997. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. J Virol 71:2463-2472.
50. Zanier K, ould M'hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, Atkinson A, Kieffer B, Trave G. 2012. Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53. Structure 20:604-617.
51. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. 1998a. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352:1441-1442.
52. Zehbe I, Wilander E, Delius H, Tommasino M. 1998b. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833.
53. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. 2001. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 94:711-716.
54. Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L. 2011. Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer 10:77.
55. Zuna RE, Moore WE, Shanesmith RP, Dunn ST, Wang SS, Schiffman M, Blakey GL, Teel T. 2009. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. Int J Cancer 125:2609-2613.
56. zur Hausen H. 2002. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2:342-350.